Since 2014, the American Association for Cancer Research (AACR) has provided the opportunity for graduate students, postdocs, and assistant professors to give high-profile presentations at the AACR Annual Meeting as part of its NextGen Stars Program. This year, 11 early-career researchers were selected based on their outstanding applications.

Learn more about one of the newest NextGen Stars below, and check out the Q&As with other members of the NextGen Stars Class of 2025.

---

Elvin Wagenblast, PhD
AACR NextGen Stars Class of 2025
Assistant Professor
Icahn School of Medicine at Mount Sinai, New York, New York

Abstract Presentation:
Developmental dependency and metabolic vulnerabilities in NUP98-rearranged pediatric leukemia

Session Details:
SY34 – Fusion Oncoprotein-driven Malignancies: From Mechanisms to Therapies
Sunday, April 27, 1-2:45 p.m. CT
Room E450 B, McCormick Lakeside Center (Level 4)

---

What is the subject of your research?

My research investigates how normal blood stem cells transform into cancerous cells, particularly in childhood leukemia. While the genetic mutations driving leukemia and the cell types that carry them are well known, we still do not fully understand how a cell’s developmental state influences its susceptibility to transformation. My work explores how the timing and context of mutation acquisition during human blood development shape leukemia initiation.

What sparked your interest in this area of research, and why is it important?

I have always been fascinated by why blood cancers emerge so early in life, sometimes even from mutations that occur before birth. Unlike adult blood cancers, which develop over decades of accumulated genetic damage, childhood leukemias arise in a vastly different biological context. Understanding why and how these early events lead to disease is not only an interesting scientific question but also essential for uncovering new approaches to prevent and treat childhood leukemia.

What (or who) inspired you to apply for the NextGen Stars program?

I was inspired to apply for the NextGen Stars program by the opportunity to highlight a different perspective in blood cancer research. Childhood leukemia arises in a unique biological context, and this platform allows me to bring attention to how early hematopoietic development influences leukemogenesis. The AACR Annual Meeting brings together an incredibly diverse audience, offering a chance to share my research and engage with experts across disciplines.

What do you hope to take away from your experience as a NextGen Star and your time at the AACR Annual Meeting 2025?

Being named an AACR NextGen Star is an exciting opportunity to engage with leading scientists and clinicians in oncology. I look forward to building new collaborations that enhance the translational impact of my work. Beyond my own research, I am eager to learn from experts in pediatric cancer, immunotherapy, and emerging technologies, gaining insights into the next major breakthroughs in cancer research.